Medovex Corporation Establishes Research and Operations Center
ATLANTA, GA -- (Marketwired) -- 02/26/15 -- Medovex Corporation (NASDAQ: MDVX), a developer of medical technology products, announced today that it has established a research and operations center in Minneapolis, Minnesota.
Strategically located in close proximity to the majority of the expert contract support vendors that the company uses for its DenerveX™ device, the center is expected to enhance accountability and performance monitoring, while allowing for important face to face collaboration. Minneapolis-St. Paul, Minnesota is recognized as a world leader in the medical technology field with corporate headquarters for some of the most renowned names in medical technology.
According to Jarrett Gorlin, CEO of Medovex, "We believe establishment of a research and operations foot print in the Minneapolis area will provide the company with enhanced access and use of experts in the medical technology space. We believe it is important for many reasons, including but not limited to, future research and development and operations supporting the DenerveX device, as well as for assisting in evaluating other technologies that the company may seek to develop or acquire."
Patrick Kullmann, President, COO of Medovex, added, "We formed Medovex to acquire and develop a diversified portfolio of potentially ground breaking medical technologies that could impact quality of patient care, cost effectiveness and wellness in a rapidly changing health care environment. Direct access to industry experts, including world class medical technology vendors in the areas of regulatory law, clinical trial development, research and development, manufacturing, reimbursement and distribution through our new research and operations center, is foundational to our mission. Minneapolis is considered by many as a world leading area for medical technology and provides a pool of talented work force candidates for future positions in the support of future growth of the company."
Medovex was formed to acquire and develop a diversified portfolio of potentially ground breaking medical technology products. Criteria for selection include those products with potential for significant improvement in the quality of patient care combined with cost effectiveness. The Company's first pipeline product, the DenerveX device, is intended to provide long lasting relief from pain associated with facet joint syndrome at significantly less cost than currently available options. To learn more about Medovex Corp., visit www.medovex.com
Safe Harbor Statement:
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the Securities and Exchange Commission (the "SEC"), not limited to Risk Factors relating to its patent business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.
Source: Medovex Corporation
Released February 26, 2015